Transgenic mice overexpressing human fibroblast growth factor 23 (R176Q) delineate a putative role for parathyroid hormone in renal phosphate wasting disorders

Endocrinology

Volumn 145, Issue 11, 2004, Pages 5269-5279

  Bai, Xiuying ^a   Miao, Dengshun ^b   Li, Jiarong ^b   Goltzman, David ^b   Karaplis, Andrew C ^a  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL; CALCIUM; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 23; FURIN; MUTANT PROTEIN; OXYGENASE; PARATHYROID HORMONE; PHOSPHATE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CALCIUM HOMEOSTASIS; CONTROLLED STUDY; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HYPOPHOSPHATEMIA; KIDNEY PROXIMAL TUBULE; KIDNEY TUBULE ABSORPTION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OSTEOMALACIA; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PHOSPHATE METABOLISM; PHOSPHATE TRANSPORT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; PROTEIN SECRETION; RENAL PHOSPHATE WASTING DISORDER; SECONDARY HYPERPARATHYROIDISM; TRANSGENIC MOUSE; VITAMIN BLOOD LEVEL; VITAMIN D METABOLISM; VITAMIN D RESISTANT RICKETS;

ANIMALS; BONE AND BONES; CALCIUM; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; FEMALE; FIBROBLAST GROWTH FACTORS; GENE EXPRESSION; HUMANS; HYPOPHOSPHATEMIA, FAMILIAL; KIDNEY TUBULES, PROXIMAL; MALE; MICE; MICE, TRANSGENIC; OSTEOMALACIA; PARATHYROID HORMONE; PHOSPHATES; PREGNANCY; VITAMIN D;

EID: 9244240970     PISSN: 00137227     EISSN: None     Source Type: Journal    
DOI: 10.1210/en.2004-0233     Document Type: Article

References (54)

1. Carpenter TO 1997 New perspectives on the biology and treatment of X-linked hypophosphatemic rickets. Pediatr Clin North Am 44:443-466
2. Econs MJ, McEnery PT 1997 Autosomal dominant hypophosphatemic rickets/osteomalacia: clinical characterization of a novel renal phosphate-wasting disorder. J Clin Endocrinol Metab 82:674-681
3. Kumar R 2000 Tumor-induced osteomalacia and the regulation of phosphate homeostasis. Bone 27:333-338
4. Dent CE, Gertner JM 1976 Hypophosphataemic osteomalacia in fibrous dysplasia. Q J Med 45:411-420
5. Shimada T, Mizutani S, Muto T, Yoneya T, Hino R, Takeda S, Takeuchi Y, Fujita T, Fukumoto S, Yamashita T 2001 Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci USA 98:6500-6505
6. Strewler GJ 2001 FGF23, hypophosphatemia, and rickets: has phosphatonin been found? Proc Natl Acad Sci USA 98:5945-5946
7. Silve C, Beck L 2002 Is FGF23 the long sought after phosphaturic factor phosphatonin? Nephrol Dial Transplant 17:958-961
8. Tenenhouse HS, Sabbagh Y 2002 Novel phosphate-regulating genes in the pathogenesis of renal phosphate wasting disorders. Pflugers Arch 444:317-326
9. Quarles LD 2003 FGF23, PHEX, and MEPE regulation of phosphate homeostasis and skeletal mineralization. Am J Physiol Endocrinol Metab 285:E1-E9
10. Berndt T, Craig TA, Bowe AE, Vassiliadis J, Reczek D, Finnegan R, Jan De Beur SM, Schiavi SC, Kumar R 2003 Secreted frizzled-related protein 4 is a potent tumor-derived phosphaturic agent. J Clin Invest 112:785-794
11. Shimada T, Kakitani M, Yamazaki Y, Hasegawa H, Takeuchi Y, Fujita T, Fukumoto S, Tomizuka K, Yamashita T 2004 Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest 113:561-568
12. The HYP Consortium 1995 A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets. Nat Genet 11:130-136
13. The ADHR Consortium 2000 Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet 26:345-348
14. White KE, Carn G, Lorenz-Depiereux B, Benet-Pages A, Strom TM, Econs MJ 2001 Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23. Kidney Int 60:2079-2086
15. Seufert J, Ebert K, Muller J, Eulert J, Hendrich C, Werner E, Schuuze N, Schulz G 2001 Octreotide therapy for tumor-induced osteomalacia. N Engl J Med 345:1883-1888
16. Riminucci M, Collins MT, Fedarko NS, Cherman N, Corsi A, White KE, Waguespack S, Gupta A, Hannon T, Econs MJ, Bianco P, Gehron Robey P 2003 FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. J Clin Invest 112:683-692
17. Bai XY, Miao D, Goltzman D, Karaplis AC 2003 The autosomal dominant hypophosphatemic rickets R176Q mutation in fibroblast growth factor 23 resists proteolytic cleavage and enhances in vivo biological potency. J Biol Chem 278:9843-9849
18. Carpenter TO 2003 Oncogenic osteomalacia: a complex dance of factors. N Engl J Med 348:1705-1708
19. Yamazaki Y, Okazaki R, Shibata M, Hasegawa Y, Satoh K, Tajima T, Takeuchi Y, Fujita T, Nakahara K, Yamashita T, Fukumoto S 2002 Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. J Clin Endocrinol Metab 87:4957-4960
20. Weber TJ, Liu S, Indridason OS, Quarles LD 2003 Serum FGF23 levels in normal and disordered phosphorus homeostasis J Bone Miner Res 18:1227-1234
21. Jonsson KB, Zahradnik R, Larsson T, White KE, Sugimoto T, Imanishi Y, Yamamoto T, Hampson G, Koshiyama H, Ljunggren O, Oba K, Yang IM, Miyauchi A, Econs MJ, Lavigne J, Juppner H 2003 Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med 348:1656-1663
22. Bowe AE, Finnegan R, Jan de Beur SM, Cho J, Levine MA, Kumar R, Schiavi SC 2001 FGF-23 inhibits renal tubular phosphate transport and is a PHEX substrate. Biochem Biophys Res Commun 284:977-981
23. Campos M, Couture C, Hirata IY, Juliano MA, Loisel TP, Crine P, Juliano L, Boileau G, Carmona AK 2003 Human recombinant endopeptidase PHEX has a strict S1′ specificity for acidic residues and cleaves peptides derived from fibroblast growth factor-23 and matrix extracellular phosphoglycoprotein. Biochem J 373:271-279
24. Liu S, Guo R, Simpson LG, Xiao ZS, Burnham CE, Quarles LD 2003 Regulation of fibroblastic growth factor 23 expression but not degradation by PHEX. J Biol Chem 278:37419-37426
25. Walton RJ, Bijvoet OL 1975 Nomogram for derivation of renal threshold phosphate concentration. Lancet 2:309-310
26. Miao D, Scutt A 2002 Recruitment, augmentation and apoptosis of rat osteoclasts in 1,25-(OH)2D3 response to short-term treatment with 1,25-dihydroxyvitamin D3 in vivo. BMC Musculoskelet Disord 3:16
27. Lopez-De Leon A, Rojkind M 1985 A simple micromethod for collagen and total protein determination in formalin-fixed paraffin-embedded sections. J Histochem Cytochem 33:737-743
28. He B, Deckelbaum RA, Miao D, Lipman ML, Pollak M, Goltzman D, Karaplis AC 2001 Tissue-specific targeting of the Pthrp gene: the generation of mice with floxed alleles. Endocrinology 142:2070-2077
29. Miao D, Scutt A 2002 Histochemical localization of alkaline phosphatase activity in decalcified bone and cartilage. J Histochem Cytochem 50:333-340
30. Miao D, Bai X, Panda D, McKee M, Karaplis A, Goltzman D 2001 Osteomalacia in hyp mice is associated with abnormal phex expression and with altered bone matrix protein expression and deposition. Endocrinology 142:926-939
31. Bai X, Miao D, Panda D, Grady S, McKee MD, Goltzman D, Karaplis AC 2002 Partial rescue of the Hyp phenotype by osteoblast-targeted PHEX (phosphate-regulating gene with homologies to endopeptidases on the X chromosome) expression. Mol Endocrinol 16:2913-2925
32. Simonet WS, Bucay N, Lauer SJ, Taylor JM 1993 A far-downstream hepatocyte-specific control region directs expression of the linked human apolipoprotein E and C-I genes in transgenic mice. J Biol Chem 268:8221-8229
33. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Sander S, Van G, Tarpley J, Derby P, Lee R, Boyle WJ 1997 Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89:309-319
34. Shimada T, Urakawa I, Yamazaki Y, Hasegawa H, Hino R, Yoneya T, Takeuchi Y, Fujita T, Fukumoto S, Yamashita T 2004 FGF-23 transgenic mice demonstrate hypophosphatemic rickets with reduced expression of sodium phosphate cotransporter type IIa. Biochem Biophys Res Commun 314:409-414
35. Larsson T, Marsell R, Schipani E, Ohlsson C, Ljunggren O, Tenenhouse HS, Juppner H, Jonsson KB 2004 Transgenic mice expressing Fibroblast growth factor 23 under the control of the α1(I) collagen promoter exhibit growth retardation, osteomalacia, and disturbed phosphate homeostasis. Endocrinology 145:3087-3094
36. Sullivan W, Carpenter T, Glorieux F, Travers R, Insogna K1992 A prospective trial of phosphate and 1,25-dihydroxyvitamin D3 therapy in symptomatic adults with X-linked hypophosphatemic rickets. J Clin Endocrinol Metab 75:879-885
37. Carpenter TO, Mitnick MA, Ellison A, Smith C, Insogna KL 1994 Nocturnal hyperparathyroidism: a frequent feature of X-linked hypophosphatemia. J Clin Endocrinol Metab 78:1378-1383
38. Knudtzon J, Halse J, Monn E, Nesland A, Nordal KP, Paus P, Seip M, Sund S, Sodal G 1995 Autonomous hyperparathyroidism in X-linked hypophosphataemia. Clin Endocrinol (Oxf) 42:199-203
39. Blydt-Hansen TD, Tenenhouse HS, Goodyer P 1999 PHEX expression in parathyroid gland and parathyroid hormone dysregulation in X-linked hypophosphatemia. Pediatr Nephrol 13:607-611
40. Kiebzak GM, Roos BA, Meyer Jr RA 1982 Secondary hyperparathyroidism in X-linked hypophosphatemic mice. Endocrinology 111:650-652
41. Meyer Jr RA, Meyer MH, Morgan PL 1996 Effects of altered diet on serum levels of 1,25-dihydroxyvitamin D and parathyroid hormone in X-linked hypophosphatemic (Hyp and Gy) mice. Bone 18:23-28
42. Ryan WG, Gitelis S, Charters JR 1986 Studies in a patient with tumor-induced hypophosphatemic osteomalacia. Calcif Tissue Int 38:358-362
43. Yang IM, Park YK, Hyun YJ, Kim DY, Woo JT, Kim SW, Kim JW, Kim YS, Choi YK 1997 Oncogenic osteomalacia caused by a phosphaturic mesenchymal tumor of the oral cavity: a case report. Korean J Intern Med 12:89-95
44. Schmitt CP, Mehls O 2004 The enigma of hyperparathyroidism in hypophosphatemic rickets. Pediatr Nephrol 19:473-477
45. Lipman ML, Panda D, Bennett HP, Henderson JE, Shane E, Shen Y, Goltzman D, Karaplis AC 1998 Cloning of human PEX cDNA. Expression, subcellular localization, and endopeptidase activity. J Biol Chem 273:13729-13737
46. Boileau G, Tenenhouse HS, Desgroseillers L, Crine P 2001 Characterization of PHEX endopeptidase catalytic activity: identification of parathyroid-hormone-related peptide 107-139 as a substrate and osteocalcin, PPi and phosphate as inhibitors. Biochem J 355(Pt 3):707-713
47. Guo R, Liu S, Spurney RF, Quarles LD 2001 Analysis of recombinant Phex: an endopeptidase in search of a substrate. Am J Physiol Endocrinol Metab 281:E837-E847
48. Shigematsu T, Kazama JJ, Yamashita T, Fukumoto S, Hosoya T, Gejyo F, Fukagawa M 2004 Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency. Am J Kidney Dis 44:250-256
49. Zierold C, Reinholz GG, Mings JA, Prahl JM, DeLuca HF 2000 Regulation of the porcine 1,25-dihydroxyvitamin D3-24-hydroxylase (CYP24) by 1,25-dihydroxyvitamin D3 and parathyroid hormone in AOK-B50 cells. Arch Biochem Biophys 381:323-327
50. Zierold C, Mings JA, DeLuca HF 2001 Parathyroid hormone regulates 25-hydroxyvitamin D(3)-24-hydroxylase mRNA by altering its stability. Proc Natl Acad Sci USA 98:13572-13576
51. Fujiwara I, Aravindan R, Horst RL, Drezner MK 2003 Abnormal regulation of renal 25-hydroxyvitamin D-1α-hydroxylase activity in X-linked hypophosphatemia: a translational or posttranslational defect. J Bone Miner Res 18:434-442
52. Beck L, Karaplis AC, Amizuka N, Hewson AS, Ozawa H, Tenenhouse HS 1998 Targeted inactivation of Npt2 in mice leads to severe renal phosphate wasting, hypercalciuria, and skeletal abnormalities. Proc Natl Acad Sci USA 95:5372-5377
53. Prie D, Huart V, Bakouh N, Planelles G, Dellis O, Gerard B, Hulin P, Benque-Blanchet F, Silve C, Grandchamp B, Friedlander G 2002 Nephrolithiasis and osteoporosis associated with hypophosphatemia caused by mutations in the type 2a sodium-phosphate cotransporter. N Engl J Med 347:983-991
54. Miao D, He B, Lanske B, Bai XY, Tong XK, Hendy GN, Goltzman D, Karaplis AC 2004 Skeletal abnormalities in Pth-null mice are influenced by dietary calcium. Endocrinology 145:2046-2053